| Secondary |
| Atrial Fibrillation |
15.9% |
| Rheumatoid Arthritis |
13.4% |
| Drug Use For Unknown Indication |
8.5% |
| Prophylaxis |
6.8% |
| Ventricular Fibrillation |
6.6% |
| Product Used For Unknown Indication |
5.7% |
| Hypertension |
4.6% |
| Embolic Stroke |
4.4% |
| Chronic Hepatitis C |
4.0% |
| Cerebral Infarction |
3.8% |
| Anticoagulant Therapy |
3.7% |
| Acute Myocardial Infarction |
3.6% |
| Pulmonary Arterial Hypertension |
3.0% |
| Dementia |
2.6% |
| Hyperlipidaemia |
2.6% |
| Premedication |
2.5% |
| Diabetes Mellitus |
2.3% |
| Colon Cancer |
2.1% |
| Cardiac Failure |
2.0% |
| Adverse Event |
1.9% |
|
| Prothrombin Time Prolonged |
23.7% |
| White Blood Cell Count Decreased |
11.5% |
| International Normalised Ratio Increased |
7.9% |
| International Normalised Ratio Abnormal |
7.2% |
| Retroperitoneal Haematoma |
5.8% |
| Pneumonia |
4.3% |
| Toxic Epidermal Necrolysis |
4.3% |
| Renal Haemorrhage |
3.6% |
| Cerebral Haemorrhage |
2.9% |
| Cystitis Haemorrhagic |
2.9% |
| Gastrointestinal Haemorrhage |
2.9% |
| Haemorrhage Subcutaneous |
2.9% |
| Hepatic Function Abnormal |
2.9% |
| Pyrexia |
2.9% |
| Shunt Occlusion |
2.9% |
| Upper Gastrointestinal Haemorrhage |
2.9% |
| Colitis Collagenous |
2.2% |
| Hypoprothrombinaemia |
2.2% |
| Liver Function Test Abnormal |
2.2% |
| Pulmonary Haemorrhage |
2.2% |
|
| Concomitant |
| Product Used For Unknown Indication |
19.7% |
| Hypertension |
10.6% |
| Drug Use For Unknown Indication |
7.4% |
| Rheumatoid Arthritis |
6.7% |
| Atrial Fibrillation |
6.3% |
| Cardiac Failure |
4.9% |
| Cerebral Infarction |
4.8% |
| Prophylaxis |
4.5% |
| Pulmonary Arterial Hypertension |
4.4% |
| Diabetes Mellitus |
4.1% |
| Eczema |
3.4% |
| Insomnia |
3.3% |
| Constipation |
3.2% |
| Hepatitis C |
2.8% |
| Pulmonary Hypertension |
2.6% |
| Heart Valve Replacement |
2.5% |
| Embolic Stroke |
2.4% |
| Hyperlipidaemia |
2.2% |
| Hyperuricaemia |
2.1% |
| Gastritis Prophylaxis |
1.8% |
|
| Off Label Use |
8.2% |
| Liver Disorder |
7.3% |
| Renal Impairment |
7.0% |
| Pneumonia |
6.7% |
| Decreased Appetite |
6.1% |
| Pyrexia |
6.1% |
| Sepsis |
6.1% |
| Hepatic Function Abnormal |
5.5% |
| White Blood Cell Count Decreased |
5.5% |
| Interstitial Lung Disease |
5.0% |
| Oedema Peripheral |
4.7% |
| Oesophageal Candidiasis |
4.7% |
| Vomiting |
4.7% |
| Cerebral Infarction |
4.4% |
| Weight Increased |
3.8% |
| Myocardial Infarction |
2.9% |
| Pleural Effusion |
2.9% |
| Renal Failure Acute |
2.9% |
| Rhabdomyolysis |
2.9% |
| Deep Vein Thrombosis |
2.6% |
|
| Interacting |
| Product Used For Unknown Indication |
11.5% |
| Myocardial Infarction |
11.2% |
| Trigeminal Neuralgia |
10.9% |
| Hypertension |
8.7% |
| Pain |
7.0% |
| Hyperlipidaemia |
6.7% |
| Oral Candidiasis |
4.6% |
| Atrial Fibrillation |
4.5% |
| Ill-defined Disorder |
4.5% |
| Drug Use For Unknown Indication |
3.7% |
| Lumbar Spinal Stenosis |
3.4% |
| Seborrhoeic Dermatitis |
3.0% |
| Angina Pectoris |
2.8% |
| Depression |
2.8% |
| Diabetes Mellitus |
2.8% |
| Insomnia |
2.5% |
| Asthma |
2.2% |
| Gastrooesophageal Reflux Disease |
2.2% |
| Thrombosis Prophylaxis |
2.2% |
| Cancer Pain |
2.1% |
|
| International Normalised Ratio Increased |
16.9% |
| Drug Interaction |
12.9% |
| Prothrombin Time Prolonged |
12.1% |
| Prothrombin Time Abnormal |
8.1% |
| Platelet Count Decreased |
5.6% |
| Haemorrhage |
4.8% |
| Hypoglycaemia |
4.8% |
| Melaena |
4.0% |
| White Blood Cell Count Increased |
4.0% |
| Wound Infection Staphylococcal |
4.0% |
| Haemorrhage Subcutaneous |
3.2% |
| Renal Impairment |
3.2% |
| Labelled Drug-drug Interaction Medication Error |
2.4% |
| Local Swelling |
2.4% |
| Mouth Haemorrhage |
2.4% |
| Rash |
2.4% |
| Subcutaneous Haematoma |
2.4% |
| Haematuria |
1.6% |
| Pulmonary Haemorrhage |
1.6% |
| Epilepsy |
0.8% |
|
